Not all fat is equal — and that changes what development needs to show email

Not all fat is equal — and that changes what development needs to show

Dear Kenneth,

Showing weight reduction is no longer sufficient to differentiate an obesity therapy. The question every development team now faces — as Professor Thomas Forst, CMO at hVIVO, puts it directly — is: ‘What is special about your drug?’

Answering that requires confronting what the evidence is actually showing: that fat distribution matters more than fat quantity, that body composition outcomes are as clinically significant as scale weight, and that the downstream cardiometabolic burden of obesity is where the real therapeutic opportunity lies.

What you will learn

Why measuring weight loss in isolation no longer satisfies regulators, payers, or the clinical community in a GLP-1-defined market
The clinical significance of ectopic fat accumulation — and why visceral fat carries disproportionate cardiometabolic risk that BMI will never capture
What the evidence shows about body composition changes when patients discontinue therapy — and why this matters for long-term programme design
How the field is moving toward dual agonists, triple agonists, and oral small molecules — and the differentiation challenge this creates

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).